Gianna focuses her practice on corporate and securities law matters for publicly traded and late-stage private companies in the life sciences, medical device, technology, and energy and sustainability industries. Gianna advises companies on SEC reporting and disclosure requirements, stock exchange requirements, and corporate governance and compliance matters. Gianna also has experience with representing issuers and investment banking firms on a variety of transactions, including initial public offerings, follow-on offerings, registered direct offerings, at-the-market offerings, private investments in public equity (PIPEs), and reverse mergers.
Experience
Select Follow-on Offering and Alternative Transaction Representations:
- Wave Life Sciences Ltd. in its $230 million follow-on offering
- Cantor Fitzgerald & Co. as lead underwriter in Zevra Therapeutics Inc.'s $60 million follow-on offering
- Canaccord Genuity and Lake Street Capital Markets as joint bookrunners in TELA Bio, Inc.'s $46 million follow-on offering
- CervoMed Inc. in its up to $149.4 million private placement
- Wave Life Sciences Ltd. in its $100 million follow-on offering
- Cantor Fitzgerald & Co. as lead underwriter in Cybin Inc.'s $8.25 million follow-on offering of units
- Leerink Partners, LLC as lead underwriter in Unity Biotechnology, Inc.'s $45 million underwritten offering
- Wave Life Sciences Ltd. in its $70 million underwritten registered direct offering
- Spero Therapeutics, Inc. in its exclusive license agreement with GSK plc.
- Guggenheim Securities, LLC as lead underwriter in Seelos Therapeutics, Inc.'s $64.5 million underwritten offering and $11.24 million registered direct offering
- Leerink Partners LLC as lead underwriter in Compass Therapeutics, Inc.'s $136 million underwritten offering
- Guggenheim Securities, LLC as lead underwriter in ANI Pharmaceuticals, Inc.'s $75 million underwritten offering
- Cantor Fitzgerald & Co. as lead underwriter in PDS Biotechnology Corporation's $52 million follow-on offering
- RBC Capital Markets, LLC as lead underwriter in Avalo Therapeutics, Inc.'s $31.5 million follow-on offering
- Quanterix Corporation in its $287.5 million follow-on offering
Select Public Mergers and Acquisitions Representations:
- Pieris Pharmaceuticals, Inc. in its reverse merger with Palvella Therapeutics, Inc.
- CervoMed Inc. (previously, EIP Pharma, Inc.) in its reverse merger with Diffusion Pharmaceuticals, Inc.
- Syncona Limited in its acquisition of Applied Genetics Technologies Corporation
- F-star Therapeutics, Inc. in its reverse merger with invoX Pharma
- ProKidney Corp. in its SPAC merger with Social Capital Suvertta Holdings Corp. III
Select Initial Public Offering Representations:
- ArriVent BioPharma, Inc. in its $200 million initial public offering
viewpoints
Public Benefit Corporations and the SPAC Surge
April 21, 2021 | Blog | By Thomas R. Burton, III, Gianna Nappi
News & Press
Mintz Advises Quaise Energy in $21M Series A1 Funding
March 14, 2024
CAMBRIDGE, Mass.—Mintz advised Quaise Energy, a developer of a new hybrid deep drilling technology for geothermal energy, in its recent $21 million Series A1 funding round. The deal brings Quaise’s total funding to more than $95 million. The investment will be used to scale up Quaise’s supply chain and enhance its field operations by improving geologic understanding at plant sites.
Mintz Advises ArriVent BioPharma on $175M Nasdaq IPO
February 01, 2024
Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.
Recognition & Awards
Phi Beta Kappa
Recent Insights
CAMBRIDGE, Mass.—Mintz advised Quaise Energy, a developer of a new hybrid deep drilling technology for geothermal energy, in its recent $21 million Series A1 funding round. The deal brings Quaise’s total funding to more than $95 million. The investment will be used to scale up Quaise’s supply chain and enhance its field operations by improving geologic understanding at plant sites.
Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.
